BME:FER
BME:FERConstruction

Ferrovial (BME:FER): Is the Recent Share Price Surge Justified by Its Current Valuation?

Ferrovial (BME:FER) has been quietly rewarding patient shareholders, with the stock climbing around 4% over the past month and more than 20% in the past 3 months despite mixed profit trends. See our latest analysis for Ferrovial. That steady 20.9% 3 month share price return feeds into a much stronger backdrop, with year to date share price gains near 39% and a 3 year total shareholder return above 130%. This suggests momentum is building as investors reassess Ferrovial's infrastructure growth...
BME:TEF
BME:TEFTelecom

Telefónica (BME:TEF) Valuation Check After Recent Share Price Drift and Portfolio Reshaping

Telefónica (BME:TEF) has been drifting lower over the past 3 months, even as its longer term 3 year and 5 year returns remain solidly positive. This sets up an interesting valuation reset. See our latest analysis for Telefónica. Over the past year, Telefónica’s share price return has slipped back while its three and five year total shareholder returns remain firmly positive. This suggests that recent weakness reflects shifting sentiment more than a broken long term story. If Telefónica’s...
BME:REN
BME:RENReal Estate

European Penny Stocks To Consider In December 2025

As the European markets continue to show strength, with the STOXX Europe 600 Index climbing 2.35% and major single-country indexes also seeing gains, investors are keenly observing the economic landscape. Amidst this backdrop of relatively subdued inflation and strategic fiscal adjustments, opportunities for growth remain a focal point for market participants. While 'penny stocks' might seem like a term from past trading eras, these smaller or newer companies can still offer significant...
BME:SAN
BME:SANBanks

Does Santander’s 2025 Valuation Still Make Sense After a 111.6% Year To Date Surge?

If you are wondering whether Banco Santander is still good value after such a massive run, you are not alone. This is exactly the right moment to dig into what the market is really pricing in. The stock has climbed 1.1% over the last week, 5.3% over the past month, and an eye catching 111.6% year to date, building on a 113.3% 1 year gain and an even more dramatic 265.0% and 295.2% over 3 and 5 years respectively. These moves have come as investors refocus on European banks amid a shifting...
BME:ITX
BME:ITXSpecialty Retail

Reassessing Inditex Valuation After Strong Multi Year Rally and Mixed Model Signals

If you are wondering whether Industria de Diseño Textil is still attractive after its substantial rise in recent years, or if the easy money has already been made, you are not alone. The stock has ticked up 3.2% over the last week and 2.4% over the past month, but it is still down 2.5% year to date and about 8.0% over the last year, trading near €49.07 after more than doubling over 3 and 5 years. Recent market chatter has focused on how Inditex is consolidating its global fashion footprint,...
BME:CBAV
BME:CBAVHealthcare

Undiscovered Gems in Europe for December 2025

As the European market continues to show resilience with the STOXX Europe 600 Index rising by 2.35%, investors are keeping a close eye on economic indicators, such as subdued inflation rates that suggest stability around the ECB's target. In this environment, identifying promising small-cap stocks becomes crucial, as these companies often offer unique growth opportunities that align well with current market dynamics and economic conditions.
BME:OHLA
BME:OHLAConstruction

OHLA (BME:OHLA) Q3 Net Loss of €17.2M Persists Despite Margin Gains, Testing Turnaround Narrative

Obrascón Huarte Lain (BME:OHLA) just released its Q3 2025 numbers with revenue of €959.8 million and net income from continuing operations of -€17.2 million. Over recent periods, the company has seen revenue move from €783.1 million in Q1 to €959.8 million in Q3, while net income slipped from -€16.7 million to -€17.2 million. Margins remain under pressure as OHLA works to return to profitability. See our full analysis for Obrascón Huarte Lain. Now that the headline numbers are out, the next...